2016 News Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
06/21/16Zogenix Announces Agreement to Refinance Debt, Further Increasing Company’s Expected 2017 Cash Balance
- Interest-only repayment provision results in $10 million increase to Zogenix’s expected cash balance at the end of 2017 - EMERYVILLE, Calif., June 21, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it has entered into an amendment to its existing term loan facility with Oxford Finance LLC and Silicon Valley Bank to provide for new term loans and partially ... 
Printer Friendly Version
06/07/16Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome
EMERYVILLE, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of the second Phase 3 clinical trial, a multi-national study (Study 1502), for the Company’s lead product candidate, ZX008, as an adjunctive treatment of seizures in children with Dravet syndrome.  ZX008 is designated as an orphan drug in both the U.S. and Europe, and received... 
Printer Friendly Version
05/31/16Zogenix to Participate in Jefferies 2016 Healthcare Conference
EMERYVILLE, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will present a corporate update at the Jefferies 2016 Healthcare Conference, which is being held in New York, NY, June 7-10, 2016. Jefferies 2016 Healthcare Conference -- Zogenix Presentation Details Date: Tuesday, J... 
Printer Friendly Version
05/10/16Zogenix Provides Corporate Update and Reports First Quarter 2016 Financial Results
Company will host a conference call today at 4:30 p.m. EDT/1:30 p.m. PDT EMERYVILLE, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the first quarter ended March 31, 2016. Corporate Update Initiated the first Phase 3 clinical trial of ZX008 in North America for the treatment of seizures ... 
Printer Friendly Version
05/05/16Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome
Patient and Caregiver Sleep Quality and Quality of Life Data Reported for First Time New Clinical Data Presented at 14th International Child Neurology Congress on the Use of Low-Dose Fenfluramine in Managing Seizures Associated With Dravet Syndrome EMERYVILLE, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced new data which continues to demonstrate ... 
Printer Friendly Version
05/03/16Zogenix to Release First Quarter 2016 Financial Results and Host Conference Call and Webcast on May 10
EMERYVILLE, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2016 after the market close, and will host a corporate update conference call and webcast on Tuesday, May 10th, at 4:30 PM Eastern Time. Tuesday, May 10th @ 4:30 PM Eastern Time/1:30 PM Pacific Time ... 
Printer Friendly Version
04/21/16New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress
Podium Presentation to Highlight Efficacy, Cardiovascular Safety, Sleep Quality, and Quality of Life in Patients Receiving Low-Dose Fenfluramine for the Treatment of Dravet Syndrome EMERYVILLE, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that new data on ZX008 (low-dose fenfluramine) will be presented at the 14th International Child Neurology C... 
Printer Friendly Version
03/10/16Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2015 Financial Results
Company will host a conference call today at 4:30 p.m. EST/1:30 p.m. PST EMERYVILLE, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the fourth quarter and year ended December 31, 2015. Corporate Update Investigational New Drug (IND) Application for the Phase 3 program for ZX008 for the... 
Printer Friendly Version
03/04/16Zogenix to Release Fourth Quarter and Full-Year 2015 Financial Results and Host Conference Call and Webcast on March 10
EMERYVILLE, Calif., March 04, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2015 after the market close, and will host a corporate update conference call and webcast on Thursday, March 10th at 4:30 PM Eastern Time. Thursday, March 10th @ 4:30 PM Eastern Time... 
Printer Friendly Version
02/03/16Zogenix to Participate in LEERINK Partners 5th Annual Global Healthcare Conference
EMERYVILLE, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Bradley S. Galer, M.D., Executive Vice President and CMO, will present a corporate update at the LEERINK Partners 5th Annual Global Healthcare Conference in New York, NY, on February 10, 2016. LEERINK Partners 5th Annual Global... 
Printer Friendly Version
01/19/16Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome
EMERYVILLE, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development program for the Company’s investigational product, ZX008, as a treatment of seizures associated with Dravet syndrome, a rare and catastrophic form of childhood epilepsy. “The FDA grantin... 
Printer Friendly Version
01/11/16Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome
SAN DIEGO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of the first Phase 3 clinical trial for the Company’s lead product candidate, ZX008, as an adjunctive treatment of seizures in children with Dravet syndrome.  “We are extremely pleased to have advanced the ZX008 program to the start of the Phase 3 trial. It is an important step towa... 
Printer Friendly Version